Kronos Bio, Inc. (KRON)
NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
After hours:
| Previous close | 0.7270 |
| Open | 0.7225 |
| Bid | 0.7358 x 200 |
| Ask | 0.7487 x 200 |
| Day's range | 0.7151 - 0.7599 |
| 52-week range | 0.6900 - 2.2900 |
| Volume | |
| Avg. volume | 373,095 |
| Market cap | 44.62M |
| Beta (5Y monthly) | 1.77 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Zacks
Down -5.63% in 4 Weeks, Here's Why Kronos Bio (KRON) Looks Ripe for a Turnaround
Kronos Bio (KRON) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
- Zacks
Kronos Bio, Inc. (KRON) Reports Q1 Loss, Tops Revenue Estimates
Kronos Bio (KRON) delivered earnings and revenue surprises of -16.28% and 68%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
- Zacks
Travere Therapeutics (TVTX) Reports Q1 Loss, Misses Revenue Estimates
Travere (TVTX) delivered earnings and revenue surprises of -79.59% and 2.70%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
© 2024 Yahoo. All rights reserved.